Recent Updates
Recently added Catalysts

CPI-444

Phase 1

Healthy Subjects | Small molecule | Other |Corvus Pharmaceuticals, Inc.|Last Updated: Jan 26, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment24
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03237988Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female SubjectsPHASE1 COMPLETED 24Jul 20, 2017Oct 4, 2017Jan 26, 20181 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
AUC0-∞: AUC from time zero to infinity
Predose through 72 hours postdose

Area under the plasma concentration-time curve (AUC) from time zero to infinity

AUC0-tz: AUC from time zero to last quantifiable concentration
Predose through 72 hours postdose

AUC from time zero to the last quantifiable concentration

%AUCex: Percentage of AUC0-∞ that was due to extrapolation from the last quantifiable concentration to infinity
Predose through 72 hours postdose

Percentage of AUC0-∞ that was due to extrapolation from the last quantifiable concentration to infinity

Secondary Endpoints
Incidence and severity of adverse events
4 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER
Treatment Arms
ArmTypeDescription
Sequence ABCACTIVE_COMPARATOR100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed).
Sequence BCAACTIVE_COMPARATOR100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted).
Sequence CABACTIVE_COMPARATOR100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted).
Interventions
NameTypeDescription
CPI-444 CapsulesDRUG100mg Capsule
CPI-444 TabletsDRUG100mg Tablets
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Males or females, of any race, 18 to 65 years of age, inclusive, at Screening. 2. Body mass index between 18.5 and 32.0 kg/m2, inclusive, at Screening. 3. In good health. 4. Females will be nonpregnant and nonlactating, and females of childbearing potential and males will agr...

Countries:United States
Unlock Eligibility Criteria